
Apellis Pharma (APLS) Stock Forecast & Price Target
Apellis Pharma (APLS) Analyst Ratings
Bulls say
Apellis Pharmaceuticals Inc. demonstrated a solid growth trajectory, with total injections increasing by 6% quarter-over-quarter and projected low to mid-single-digit growth for the remainder of the year, indicating a stable demand for its products. The company anticipates accelerated growth in the long term driven by market expansion efforts, including direct-to-consumer campaigns, referral programs, and educational initiatives aimed at healthcare practitioners, particularly in light of recent positive tissue preservation data updates. Additionally, financial updates reflect an increased revenue forecast for Empaveli by approximately 9 to 10% due to recent approvals, alongside reduced projected R&D expenses, thereby highlighting improved financial efficiency and revenue potential.
Bears say
Apellis Pharmaceuticals faces significant commercial risks that could adversely affect its financial outlook, including potential setbacks from increased competition, such as Izervay, and the uncertainty surrounding the launch of its C3G treatment, which may be less common than anticipated. Additionally, financial analysts note that the company's growth projections for geographic atrophy (GA) are lower than those from competitors, raising concerns about market share and acceptance, particularly in relation to existing treatments like Soliris and Ultomiris. Lastly, the risk of adverse clinical outcomes, such as reported instances of retinal vasculitis, poses further threats to the commercial viability and future revenues of Apellis's products.
This aggregate rating is based on analysts' research of Apellis Pharma and is not a guaranteed prediction by Public.com or investment advice.
Apellis Pharma (APLS) Analyst Forecast & Price Prediction
Start investing in Apellis Pharma (APLS)
Order type
Buy in
Order amount
Est. shares
0 shares